Klinik, Morphologie und Prognose chronischer myelomonozytärer Leukämien View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1999-09

AUTHORS

Ulrich Germing, Corinna Strupp, Gerald Meckenstock, Aristoteles Giagounidis, Horst Minning, Carlo Aul

ABSTRACT

□ BackgroundThe FAB group proposed to distinguish 2 subgroups of chronic myelomonocytic leukemia (CMML): Depending on the total leukocyte count a myelodysplastic type (<13,000/μl) was separated from a myeloproliferative type (>13,000/μl). Prognostic factors are not well-established until now.□ Patients and MethodsBased on retrospective analyses of patients with CMML diagnosed at our institution, we compared the presenting clinical and hematological features of both disorders and examined the natural course of the disease and prognostic factors.□ ResultsOut of 225 patients with CMML there were 115 patients with myelodysplastic type (MDS-CMML) and 110 patients with myeloproliferative type (MPD-CMML). Median age of patients at diagnosis and sex ratio were not different. Splenomegaly and hepatomegaly were more common in MPD-CMML. With regard to laboratory findings, patients with MPD-CMML presented with significantly higher LDH values. Except for WBC, peripheral blood counts were not different. Median percentage of bone marrow blasts was 8% in both disorders. Signs of bone marrow dysplasia were comparable in both disorders. Cumulative survival rates were similar in both disorders. Five years after diagnosis, actuarial survival for patients with MPD-CMML was 24%, as compared to 15% for patients with MDS-CMML. The probability of transformation to AML was higher in MDS-CMML (29% vs 18% after 5 years). Elevated LDH values, low hemoglobin values and male sex were independent risk factors for the entire group and for the MDS-CMML group. Using the Düsseldorf score, we could define risk groups within MDS-CMML with a median survial of 12 vs 40 months (p=0.00005). Prognostic factors could not define risk groups within the MPD-CMML group.□ ConclusionsIn summary, these data suggest that MDS-CMML and MPD-CMML are clinically distinguishing conditions, but the separation provides little prognostic information. The Düsseldorf score can be used to provide risk stratification in CMML. More... »

PAGES

467-472

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf03044937

DOI

http://dx.doi.org/10.1007/bf03044937

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1017520381

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/10544608


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Progression", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia, Myeloid, Acute", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia, Myelomonocytic, Chronic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukocyte Count", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Klinik f\u00fcr H\u00e4matologie, Onkologie and klinische Immunologie der Universit\u00e4t, Moorenstra\u00dfe 5, D-40225, D\u00fcsseldorf, Deutschland", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Klinik f\u00fcr H\u00e4matologie, Onkologie and klinische Immunologie der Universit\u00e4t, Moorenstra\u00dfe 5, D-40225, D\u00fcsseldorf, Deutschland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Germing", 
        "givenName": "Ulrich", 
        "id": "sg:person.01362464041.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362464041.20"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Strupp", 
        "givenName": "Corinna", 
        "id": "sg:person.01001653715.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001653715.11"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Meckenstock", 
        "givenName": "Gerald", 
        "id": "sg:person.01017743131.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017743131.87"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Giagounidis", 
        "givenName": "Aristoteles", 
        "id": "sg:person.01164215515.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164215515.10"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Minning", 
        "givenName": "Horst", 
        "id": "sg:person.0745510212.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0745510212.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Klinik f\u00fcr H\u00e4matologie, Onkologie and klinische Immunologie der Universit\u00e4t, Moorenstra\u00dfe 5, D-40225, D\u00fcsseldorf, Deutschland", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Klinik f\u00fcr H\u00e4matologie, Onkologie and klinische Immunologie der Universit\u00e4t, Moorenstra\u00dfe 5, D-40225, D\u00fcsseldorf, Deutschland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Aul", 
        "givenName": "Carlo", 
        "id": "sg:person.01300444115.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300444115.40"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/bjc.1987.154", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009723275", 
          "https://doi.org/10.1038/bjc.1987.154"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1999-09", 
    "datePublishedReg": "1999-09-01", 
    "description": "Abstract\u25a1 BackgroundThe FAB group proposed to distinguish 2 subgroups of chronic myelomonocytic leukemia (CMML): Depending on the total leukocyte count a myelodysplastic type (<13,000/\u03bcl) was separated from a myeloproliferative type (>13,000/\u03bcl). Prognostic factors are not well-established until now.\u25a1 Patients and MethodsBased on retrospective analyses of patients with CMML diagnosed at our institution, we compared the presenting clinical and hematological features of both disorders and examined the natural course of the disease and prognostic factors.\u25a1 ResultsOut of 225 patients with CMML there were 115 patients with myelodysplastic type (MDS-CMML) and 110 patients with myeloproliferative type (MPD-CMML). Median age of patients at diagnosis and sex ratio were not different. Splenomegaly and hepatomegaly were more common in MPD-CMML. With regard to laboratory findings, patients with MPD-CMML presented with significantly higher LDH values. Except for WBC, peripheral blood counts were not different. Median percentage of bone marrow blasts was 8% in both disorders. Signs of bone marrow dysplasia were comparable in both disorders. Cumulative survival rates were similar in both disorders. Five years after diagnosis, actuarial survival for patients with MPD-CMML was 24%, as compared to 15% for patients with MDS-CMML. The probability of transformation to AML was higher in MDS-CMML (29% vs 18% after 5 years). Elevated LDH values, low hemoglobin values and male sex were independent risk factors for the entire group and for the MDS-CMML group. Using the D\u00fcsseldorf score, we could define risk groups within MDS-CMML with a median survial of 12 vs 40 months (p=0.00005). Prognostic factors could not define risk groups within the MPD-CMML group.\u25a1 ConclusionsIn summary, these data suggest that MDS-CMML and MPD-CMML are clinically distinguishing conditions, but the separation provides little prognostic information. The D\u00fcsseldorf score can be used to provide risk stratification in CMML.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/bf03044937", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1358069", 
        "issn": [
          "0025-8458", 
          "1615-6722"
        ], 
        "name": "Medizinische Klinik", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "9", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "94"
      }
    ], 
    "keywords": [
      "chronic myelomonocytic leukemia", 
      "prognostic factors", 
      "myeloproliferative type", 
      "risk groups", 
      "LDH values", 
      "elevated LDH values", 
      "little prognostic information", 
      "bone marrow dysplasia", 
      "independent risk factor", 
      "bone marrow blasts", 
      "cumulative survival rate", 
      "peripheral blood counts", 
      "lower hemoglobin values", 
      "higher LDH values", 
      "actuarial survival", 
      "marrow dysplasia", 
      "marrow blasts", 
      "median age", 
      "risk stratification", 
      "male sex", 
      "blood count", 
      "total leukocytes", 
      "laboratory findings", 
      "natural course", 
      "risk factors", 
      "prognostic information", 
      "hemoglobin values", 
      "myelomonocytic leukemia", 
      "retrospective analysis", 
      "FAB group", 
      "hematological features", 
      "patients", 
      "median percentage", 
      "survival rate", 
      "entire group", 
      "disorders", 
      "ConclusionsIn summary", 
      "diagnosis", 
      "group", 
      "scores", 
      "hepatomegaly", 
      "ResultsOut", 
      "splenomegaly", 
      "factors", 
      "dysplasia", 
      "leukemia", 
      "AML", 
      "WBC", 
      "leukocytes", 
      "disease", 
      "months", 
      "survival", 
      "Klinik", 
      "age", 
      "subgroups", 
      "sex", 
      "survial", 
      "signs", 
      "probability of transformation", 
      "Leuk\u00e4mien", 
      "count", 
      "MethodsBased", 
      "sex ratio", 
      "stratification", 
      "years", 
      "findings", 
      "percentage", 
      "blasts", 
      "course", 
      "types", 
      "summary", 
      "rate", 
      "regard", 
      "values", 
      "data", 
      "institutions", 
      "ratio", 
      "analysis", 
      "features", 
      "information", 
      "conditions", 
      "probability", 
      "transformation", 
      "separation"
    ], 
    "name": "Klinik, Morphologie und Prognose chronischer myelomonozyt\u00e4rer Leuk\u00e4mien", 
    "pagination": "467-472", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1017520381"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf03044937"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "10544608"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf03044937", 
      "https://app.dimensions.ai/details/publication/pub.1017520381"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T16:54", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_318.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/bf03044937"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf03044937'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf03044937'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf03044937'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf03044937'


 

This table displays all metadata directly associated to this object as RDF triples.

232 TRIPLES      21 PREDICATES      124 URIs      115 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf03044937 schema:about N0b49f774b9ea48989ba8d16a899bc7a8
2 N136e89043d2d4f2d9e795017a1d63231
3 N14d4d01524ac4ac5a4a7ffeae4fc9d1b
4 N1b9af5ba88274cf896bd06015de52394
5 N2b977d1917874ae1bd5b770015c68f23
6 N2c061474ffc048fa8f35db1bff008660
7 N3ec55f13c54f4383a475d099ba59ec09
8 N43fc015f2fab4974bac5e3b7ddf387f1
9 N6a758d7fcc7f4a91a7559c04dbb78af5
10 N8f719f804bf048a29bd96795f3529bbc
11 Na643b38dc39446f489f567a500e33a27
12 Nf2082f75875b4012bc1b5b7a70613dd1
13 Nf763d6d9d11842bca51ad75140623ac4
14 anzsrc-for:11
15 anzsrc-for:1102
16 schema:author N6c3c8c4f907643bea655ebbc150e81b2
17 schema:citation sg:pub.10.1038/bjc.1987.154
18 schema:datePublished 1999-09
19 schema:datePublishedReg 1999-09-01
20 schema:description Abstract□ BackgroundThe FAB group proposed to distinguish 2 subgroups of chronic myelomonocytic leukemia (CMML): Depending on the total leukocyte count a myelodysplastic type (<13,000/μl) was separated from a myeloproliferative type (>13,000/μl). Prognostic factors are not well-established until now.□ Patients and MethodsBased on retrospective analyses of patients with CMML diagnosed at our institution, we compared the presenting clinical and hematological features of both disorders and examined the natural course of the disease and prognostic factors.□ ResultsOut of 225 patients with CMML there were 115 patients with myelodysplastic type (MDS-CMML) and 110 patients with myeloproliferative type (MPD-CMML). Median age of patients at diagnosis and sex ratio were not different. Splenomegaly and hepatomegaly were more common in MPD-CMML. With regard to laboratory findings, patients with MPD-CMML presented with significantly higher LDH values. Except for WBC, peripheral blood counts were not different. Median percentage of bone marrow blasts was 8% in both disorders. Signs of bone marrow dysplasia were comparable in both disorders. Cumulative survival rates were similar in both disorders. Five years after diagnosis, actuarial survival for patients with MPD-CMML was 24%, as compared to 15% for patients with MDS-CMML. The probability of transformation to AML was higher in MDS-CMML (29% vs 18% after 5 years). Elevated LDH values, low hemoglobin values and male sex were independent risk factors for the entire group and for the MDS-CMML group. Using the Düsseldorf score, we could define risk groups within MDS-CMML with a median survial of 12 vs 40 months (p=0.00005). Prognostic factors could not define risk groups within the MPD-CMML group.□ ConclusionsIn summary, these data suggest that MDS-CMML and MPD-CMML are clinically distinguishing conditions, but the separation provides little prognostic information. The Düsseldorf score can be used to provide risk stratification in CMML.
21 schema:genre article
22 schema:isAccessibleForFree false
23 schema:isPartOf N2b0fccb634204eb5910ca355e7432443
24 Na7a5f94a254e45ddb4f93165e30b8de1
25 sg:journal.1358069
26 schema:keywords AML
27 ConclusionsIn summary
28 FAB group
29 Klinik
30 LDH values
31 Leukämien
32 MethodsBased
33 ResultsOut
34 WBC
35 actuarial survival
36 age
37 analysis
38 blasts
39 blood count
40 bone marrow blasts
41 bone marrow dysplasia
42 chronic myelomonocytic leukemia
43 conditions
44 count
45 course
46 cumulative survival rate
47 data
48 diagnosis
49 disease
50 disorders
51 dysplasia
52 elevated LDH values
53 entire group
54 factors
55 features
56 findings
57 group
58 hematological features
59 hemoglobin values
60 hepatomegaly
61 higher LDH values
62 independent risk factor
63 information
64 institutions
65 laboratory findings
66 leukemia
67 leukocytes
68 little prognostic information
69 lower hemoglobin values
70 male sex
71 marrow blasts
72 marrow dysplasia
73 median age
74 median percentage
75 months
76 myelomonocytic leukemia
77 myeloproliferative type
78 natural course
79 patients
80 percentage
81 peripheral blood counts
82 probability
83 probability of transformation
84 prognostic factors
85 prognostic information
86 rate
87 ratio
88 regard
89 retrospective analysis
90 risk factors
91 risk groups
92 risk stratification
93 scores
94 separation
95 sex
96 sex ratio
97 signs
98 splenomegaly
99 stratification
100 subgroups
101 summary
102 survial
103 survival
104 survival rate
105 total leukocytes
106 transformation
107 types
108 values
109 years
110 schema:name Klinik, Morphologie und Prognose chronischer myelomonozytärer Leukämien
111 schema:pagination 467-472
112 schema:productId N081116bbea424dbf818ebe988c1f4d52
113 N1e8dfc42375046899d43b91578d555cb
114 N32e07914b5cc41d7bbf34edac2b58529
115 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017520381
116 https://doi.org/10.1007/bf03044937
117 schema:sdDatePublished 2022-08-04T16:54
118 schema:sdLicense https://scigraph.springernature.com/explorer/license/
119 schema:sdPublisher N4358e0c72ad64afe886807094b2b7a08
120 schema:url https://doi.org/10.1007/bf03044937
121 sgo:license sg:explorer/license/
122 sgo:sdDataset articles
123 rdf:type schema:ScholarlyArticle
124 N02b75b7b63fc426f8c1bd3d9d02ee917 rdf:first sg:person.01300444115.40
125 rdf:rest rdf:nil
126 N081116bbea424dbf818ebe988c1f4d52 schema:name dimensions_id
127 schema:value pub.1017520381
128 rdf:type schema:PropertyValue
129 N0b49f774b9ea48989ba8d16a899bc7a8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Female
131 rdf:type schema:DefinedTerm
132 N136e89043d2d4f2d9e795017a1d63231 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Humans
134 rdf:type schema:DefinedTerm
135 N14d4d01524ac4ac5a4a7ffeae4fc9d1b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Leukemia, Myeloid, Acute
137 rdf:type schema:DefinedTerm
138 N1b9af5ba88274cf896bd06015de52394 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Aged, 80 and over
140 rdf:type schema:DefinedTerm
141 N1e8dfc42375046899d43b91578d555cb schema:name pubmed_id
142 schema:value 10544608
143 rdf:type schema:PropertyValue
144 N2b0fccb634204eb5910ca355e7432443 schema:volumeNumber 94
145 rdf:type schema:PublicationVolume
146 N2b977d1917874ae1bd5b770015c68f23 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Aged
148 rdf:type schema:DefinedTerm
149 N2c061474ffc048fa8f35db1bff008660 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Prognosis
151 rdf:type schema:DefinedTerm
152 N32e07914b5cc41d7bbf34edac2b58529 schema:name doi
153 schema:value 10.1007/bf03044937
154 rdf:type schema:PropertyValue
155 N3ec55f13c54f4383a475d099ba59ec09 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Survival Analysis
157 rdf:type schema:DefinedTerm
158 N4358e0c72ad64afe886807094b2b7a08 schema:name Springer Nature - SN SciGraph project
159 rdf:type schema:Organization
160 N43fc015f2fab4974bac5e3b7ddf387f1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Disease Progression
162 rdf:type schema:DefinedTerm
163 N4db16f082e2e4accbaf2ba946d582580 rdf:first sg:person.01164215515.10
164 rdf:rest Nde491b1754ae4878956f2d0f5c0ccd71
165 N6a758d7fcc7f4a91a7559c04dbb78af5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Middle Aged
167 rdf:type schema:DefinedTerm
168 N6c3c8c4f907643bea655ebbc150e81b2 rdf:first sg:person.01362464041.20
169 rdf:rest Nb519d733f04c4af49041e0817ec7a946
170 N8f719f804bf048a29bd96795f3529bbc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Male
172 rdf:type schema:DefinedTerm
173 N9290dfcf18f040cca83abce7d319d744 rdf:first sg:person.01017743131.87
174 rdf:rest N4db16f082e2e4accbaf2ba946d582580
175 Na643b38dc39446f489f567a500e33a27 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Leukocyte Count
177 rdf:type schema:DefinedTerm
178 Na7a5f94a254e45ddb4f93165e30b8de1 schema:issueNumber 9
179 rdf:type schema:PublicationIssue
180 Nb519d733f04c4af49041e0817ec7a946 rdf:first sg:person.01001653715.11
181 rdf:rest N9290dfcf18f040cca83abce7d319d744
182 Nde491b1754ae4878956f2d0f5c0ccd71 rdf:first sg:person.0745510212.07
183 rdf:rest N02b75b7b63fc426f8c1bd3d9d02ee917
184 Nf2082f75875b4012bc1b5b7a70613dd1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Adult
186 rdf:type schema:DefinedTerm
187 Nf763d6d9d11842bca51ad75140623ac4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Leukemia, Myelomonocytic, Chronic
189 rdf:type schema:DefinedTerm
190 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
191 schema:name Medical and Health Sciences
192 rdf:type schema:DefinedTerm
193 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
194 schema:name Cardiorespiratory Medicine and Haematology
195 rdf:type schema:DefinedTerm
196 sg:journal.1358069 schema:issn 0025-8458
197 1615-6722
198 schema:name Medizinische Klinik
199 schema:publisher Springer Nature
200 rdf:type schema:Periodical
201 sg:person.01001653715.11 schema:familyName Strupp
202 schema:givenName Corinna
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001653715.11
204 rdf:type schema:Person
205 sg:person.01017743131.87 schema:familyName Meckenstock
206 schema:givenName Gerald
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017743131.87
208 rdf:type schema:Person
209 sg:person.01164215515.10 schema:familyName Giagounidis
210 schema:givenName Aristoteles
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164215515.10
212 rdf:type schema:Person
213 sg:person.01300444115.40 schema:affiliation grid-institutes:None
214 schema:familyName Aul
215 schema:givenName Carlo
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300444115.40
217 rdf:type schema:Person
218 sg:person.01362464041.20 schema:affiliation grid-institutes:None
219 schema:familyName Germing
220 schema:givenName Ulrich
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362464041.20
222 rdf:type schema:Person
223 sg:person.0745510212.07 schema:familyName Minning
224 schema:givenName Horst
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0745510212.07
226 rdf:type schema:Person
227 sg:pub.10.1038/bjc.1987.154 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009723275
228 https://doi.org/10.1038/bjc.1987.154
229 rdf:type schema:CreativeWork
230 grid-institutes:None schema:alternateName Klinik für Hämatologie, Onkologie and klinische Immunologie der Universität, Moorenstraße 5, D-40225, Düsseldorf, Deutschland
231 schema:name Klinik für Hämatologie, Onkologie and klinische Immunologie der Universität, Moorenstraße 5, D-40225, Düsseldorf, Deutschland
232 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...